Harford W V, Krejs G J, Santa Ana C A, Fordtran J S
Gastroenterology. 1980 Mar;78(3):440-3.
Fifteen patients with chronic diarrhea and fecal incontinence were admitted to a clinical research center and treated for 3 days with either placebo or diphenoxylate with atropine (Lomotil). The patients were then crossed over to the alternate medication. Lomotil had no effect on rectal or anal sphincter pressure or on continence for saline that had been infused into the rectum. However, Lomotil therapy reduced average stool frequency (from 4.9 to 2.6 times/day) and average stool weight (from 460 to 256 g/day). These results suggest that temporary or intermittent therapy with Lomotil and related drugs might benefit patients with chronic diarrhea and fecal incontinence. They should do this by virtue of a reduction in stool frequency and stool volume, without a deleterious effect on the defense mechanisms against incontinence.
15名患有慢性腹泻和大便失禁的患者被收治到一个临床研究中心，接受了3天的安慰剂或地芬诺酯阿托品复方制剂（易蒙停）治疗。然后患者交叉使用另一种药物。易蒙停对直肠或肛门括约肌压力以及注入直肠的生理盐水的控尿能力没有影响。然而，易蒙停治疗降低了平均排便频率（从每天4.9次降至2.6次）和平均粪便重量（从每天460克降至256克）。这些结果表明，使用易蒙停及相关药物进行临时或间歇性治疗可能会使慢性腹泻和大便失禁患者受益。它们应该是通过降低排便频率和粪便量来实现这一点，而不会对防止失禁的防御机制产生有害影响。
